Sherbrooke Park Advisers LLC Terns Pharmaceuticals, Inc. Call Options Transaction History
Sherbrooke Park Advisers LLC
- $313 Billion
- Q4 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding TERN
# of Institutions
159Shares Held
83.7MCall Options Held
473KPut Options Held
119K-
Soleus Capital Management, L.P. Greenwich, CT8.14MShares$33.5 Million3.16% of portfolio
-
Orbimed Advisors LLC San Diego, CA7.56MShares$31.2 Million1.14% of portfolio
-
Vivo Capital, LLC Palo Alto, CA6.9MShares$28.4 Million7.51% of portfolio
-
Deep Track Capital, LP Greenwich, CT5.58MShares$23 Million1.37% of portfolio
-
Schonfeld Strategic Advisors LLC New York, NY4.75MShares$19.6 Million0.17% of portfolio
About Terns Pharmaceuticals, Inc.
- Ticker TERN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,613,800
- Market Cap $155M
- Description
- Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...